Consensus Adverum Biotechnologies, Inc.

Equities

ADVM

US00773U2078

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
14.66 USD +3.60% Intraday chart for Adverum Biotechnologies, Inc. -3.55% +94.74%

Evolution of the average Target Price on Adverum Biotechnologies, Inc.

Price target over the last 5 years

History of analyst recommendation changes

a423d59bacfe28cae46c2fcb.N6rMncY6pJ5ZjhpCtSvBt0G1rLYUXTaSgweD2mld7Fc.WcuO059e--YfvXB1jHqI-huFleVgaFLN5VbT6z1sqC1G-6PLlmvC6xXZfQ~4d941ec930e035f23a40b659603fe716
RBC Cuts Price Target on Adverum Biotechnologies to $2 From $3, Keeps Sector Perform, Speculative Risk MT
Mizuho Starts Adverum Biotechnologies With Buy Rating, Price Target is $2 MT
Chardan Upgrades Adverum Biotechnologies to Buy From Neutral, Expecting Positive Outcome From Ongoing LUNA Trial, Raises Price Target to $4 From $2 MT
Ladenburg Thalmann Starts Adverum Biotechnologies at Buy With $2 Price Target MT
RBC Cuts Price Target on Adverum Biotechnologies to $3 From $5, Maintains Sector Perform, Speculative Risk MT
Chardan Trims Price Target on Adverum Biotechnologies to $2 From $2.50, Retains Neutral Rating MT
Chardan Research Trims Adverum Biotechnologies' Price Target to $2.50 From $3, Maintains Neutral Rating MT
Truist Securities Upgrades Adverum Biotechnologies to Buy From Hold, Adjusts Price Target to $4 From $3 MT
CORRECTION : --Goldman Sachs Downgrades Advantage Solutions to Neutral From Buy; Price Target is $7 MT
ADVERUM BIOTECHNOLOGIES : Goldman Sachs Downgrades Adverum Biotechnologies to Neutral From Buy, Adjusts PT to $3 From $10 MT
ADVERUM BIOTECHNOLOGIES : Chardan Adjusts Price Target on Adverum Biotechnologies to $3 From $5 After Eye Drug Cancellation, Maintains Neutral Rating MT
ADVERUM BIOTECHNOLOGIES : SVB Leerink Adjusts Adverum Biotechnologies' Price Target to $2 from $5, Keeps Market Perform Rating MT
ADVERUM BIOTECHNOLOGIES : Cantor Fitzgerald Downgrades Adverum Biotechnologies to Neutral From Overweight, Adjusts Price Target to $3 From $23 MT
ADVERUM BIOTECHNOLOGIES : SVB Leerink Downgrades Adverum Biotechnologies to Market Perform From Outperform; Price Target is $5 MT
ADVERUM BIOTECHNOLOGIES : Goldman Sachs Adjusts Price Target for Adverum Biotechnologies to $10 From $28, Maintains Buy Rating MT
ADVERUM BIOTECHNOLOGIES : Truist Securities Downgrades Adverum Biotechnologies to Hold From Buy, Adjusts PT to $9 From $30 MT
ADVERUM BIOTECHNOLOGIES : Chardan Downgrades Adverum Biotechnologies to Neutral Rating From Buy on Eye Drug Side Effects, Adjusts Price Target to $5 From $20 MT
ADVERUM BIOTECHNOLOGIES : RBC Capital Downgrades Adverum Biotechnologies to Sector Perform Rating From Outperform, Lowers PT to $6 From $30 MT
ADVERUM BIOTECHNOLOGIES : SVB Leerink Adjusts Price Target on Adverum Biotechnologies to $11 From $21, Maintains Outperform Rating MT
ADVERUM BIOTECHNOLOGIES : UBS Adjusts Price Target on Adverum Biotechnologies to $12 From $13, Maintains Neutral Rating MT
ADVERUM BIOTECHNOLOGIES : UBS Starts Adverum Biotechnologies at Neutral With $13 Price Target MT
ADVERUM BIOTECHNOLOGIES : Raymond James Upgrades Adverum Biotechnologies to Market Perform From Underperform MT
ADVERUM BIOTECHNOLOGIES : Goldman Sachs Adjusts Price Target for Adverum Biotechnologies to $25 From $27, Maintains Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
14.66 USD
Average target price
40 USD
Spread / Average Target
+172.85%
High Price Target
60 USD
Spread / Highest target
+309.28%
Low Price Target
20 USD
Spread / Lowest Target
+36.43%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Adverum Biotechnologies, Inc.

RBC Capital Markets
Mizuho Securities
Chardan Research
Ladenburg Thalmann
Truist Securities
SVB Leerink
Cantor Fitzgerald
Chardan
Goldman Sachs
UBS
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings